Filter Free Mode Research Articles

Development of a dose-rate dosimeter using a silicon photodiode for a medical linear accelerator in a 10 MV flattening filter-free mode.

This study was aimed at developing a dose-rate dosimeter to measure the instantaneous dose rate of a commercially available medical linear accelerator. A dose-rate dosimeter composed of a silicon photodiode (Si-PD), a complementary metal-oxide semiconductor single operational amplifier, a resistor of 20 MΩ, a capacitor of 100 pF, and a mini-substrate measuring 16 × 16mm2 was evaluated. Voltage outputs from the proposed dosimeter were measured using an analog-to-digital converter on a microcomputer. A custom-made x-ray tube generator at an energy of 120kV with a tube current ranging from 0.1 to 2.0 mA was used for the dose-rate calibration. Dose-rate calibration was performed 83.3mm from an x-ray source using a commercially available semiconductor dosimeter. The developed Si-PD dosimeter could measure up to 0.6 Gy/s at a distance of 19.3mm from the x-ray source. Measurements were also performed using a medical linear accelerator in a 10 MV flattening filter-free mode at depths of 0, 25, 50, and 100mm with an irradiation field of 100 × 100mm2 at a constant distance of 1000mm from the source to the dosimeter. A peak voltage variation corresponding to the instantaneous dose rate was observed using a sampling period of 1.0ms, and the peak voltages decreased with the depth. The detected pulse numbers were 512, 484, 491, and 511 at depths of 0, 25, 50, and 100mm, respectively.

AAPM WGVRTO report 390: A survey of veterinary radiation oncology equipment and infrastructure in 2022.

Since 2010, there has been little published data on the state of equipment and infrastructure in veterinary radiation oncology clinical practice. These data are important not only to identify the status and use of technology within the veterinary radiation oncology community but also to help identify the extent of medical physics support. The purpose of our study is to report findings from a survey of veterinary radiation oncologists in the USA, Canada, and select centers outside of North America in 2022. A 40-question survey covering topics such as type of radiotherapy equipment, techniques offered, treatment planning systems and dose calculation algorithms, special techniques, board-certified radiation oncologists and residents, and extent of medical physics support was distributed through an online survey tool. Results from 40 veterinary radiation oncology institutions, with equipment explicitly used for veterinary care, suggest that the current state of practice is not dissimilar to what currently exists in human radiation oncology facilities; techniques and technologies commonly employed include flattening filter-free mode megavoltage beams, volumetric arc therapy, daily cone-beam computed tomography, image-guided radiation therapy, and sophisticated dose calculation algorithms. These findings suggest the need for modern radiation oncology acceptance testing, commissioning, and quality assurance programs within the veterinary community. The increase in veterinary radiation oncology residency positions and increasing sophistication of equipment suggests that increased levels of standardized medical physics support would benefit the veterinary radiation oncology community.

Novel frameless LINAC radiosurgery solution for uveal melanoma.

Radiation treatment has replaced enucleation as an organ-preservation treatment for patients with uveal melanoma (UM). We developed a novel non-invasive, frameless LINAC based solution for fractionated stereotactic radiosurgery (fSRS) treatment. We designed and constructed the a stereotactic ocular localization box that can be attached and indexed to a stereotactic LINAC tabletop. It contains adjustable LED lights as a gaze focus point and CCD camera for monitoring of the patient's eye position. The device also has 6 infrared spheres compatible with the ExacTRAC IGRT system. Treatment plans were developed using iPLAN Dose version 4.5, with conformal dynamic arcs and 6MV photon beam in flattening filter free mode, dosed to 50Gy in 5 fractions. During treatment, patients were instructed to stare at the light when a radiation beam is prepared and ready for delivery. Eye movement was tracked throughout treatment. Residual setup errors were recorded for evaluation. The stereotactic ocular localization box was 3D-printed with polylactic acid material and attached to the stereotactic LINAC tabletop. 10 patients were treated to evaluate the feasibility, tolerability and setup accuracy. Median treatment time for each arc is 17.3 ± 2.4 seconds (range: 13.8-23.4). After ExacTRAC setup, the residual setup errors are -0.1 ± 0.3mm laterally, -0.1 ± 0.3mm longitudinally, and 0 ± 0.2mm vertically. The residue rotational errors are -0.1 ± 0.3 degree pitch, 0.1 ± 0.2 degree roll, and 0 ± 0.2 degree couch rotation. All patients received treatment successfully. We successfully developed a novel non-invasive frameless mask-based LINAC solution for SRS for uveal melanoma, or other ocular tumors. It is well tolerated with high set up accuracy. Future directions for this localization box would include a multi-center trial to assess the efficacy and reproducibility in the fabrication and execution of such a solution for UM therapy.

Dosimetric parameters calculation for 18 MV photon beam in flattening filter (FF) and flattening filter free (FFF) linear accelerators with and without magnetic deflector and lead filter

Dosimetric characteristics of the flattening filter (FF) and flattening filter free (FFF) modes of 18 MV therapeutic photon beam were investigated with and without the magnetic deflector (MD) and lead filter. MCNP version 6.1.0 Monte Carlo (MC) code was used to simulate the 18 MV photon beam of 2100 C/D-Varian linear accelerator (LINAC) for the FF and FFF modes. The MD (uniform magnetic flux density of 1 Tesla) and lead filter (thickness of 1 mm) were modeled to remove contaminant electrons. The dosimetric parameters for different scenarios of LINAC’s head were calculated. Removing the flattening filter in the FFF mode increased the dose rate, electron contamination, skin dose, out-of-field dose, and un-flatness compared to the FF mode. While the lead filter decreased the contaminant electrons significantly, using the MD removed all secondary electrons from the beam line. The surface dose was decreased by 8.3% and 11.2% for the magnetic deflector (MD) and lead filter in the FF mode, respectively. The surface dose was decreased by 16.8% and 20.3% for the MD and lead filter scenarios in the FFF mode, respectively. The MD and lead filter decreased surface penumbra by 15.5% and 11.5% compared to the FFF mode. Removing the flattening filter from the LINAC’s head improves most of the dosimetric characteristics of the 18MV therapeutic beam. The use of a lead filter and magnetic deflector preserves the skin-sparing property of megavoltage beams that deteriorate in FFF mode. However, using a magnetic deflector does not reduce photon fluence and dose rate.

FLASH radiotherapy using high-energy X-rays: Current status of PARTER platform in FLASH research

PurposeRecent studies indicated that ultrahigh dose rate (FLASH) radiation can reduce damage to normal tissue while maintaining anti-tumour activity compared to conventional dose rate (CONV) radiation. This paper provides a comprehensive description of the current status of the Platform for Advanced Radiotherapy Research (PARTER), which serves as the first experimental FLASH platform utilizing megavoltage X-rays and has facilitated numerous experiments. Methods and MaterialsPARTER was established in 2019 based on a superconducting linac to support experimental FLASH studies using megavoltage X-rays. Continuous upgrades have been made to the accelerator, collimators, flattening filters, monitors, other auxiliary devices, and irradiation process in order to achieve optimal results. Passive and active dosimeters are employed for measuring dose distribution and to ensure traceability of radiation doses. ResultsThe dose monitors and dosimeters demonstrate reliable performance with acceptable stability. At PARTER, the maximum mean dose rate is approximately 400 Gy/s at a surface-source distance of 20 cm (over 1000 Gy/s at smaller distances), with an instantaneous dose rate of approximately 8E5 Gy/s. Both passive and active dosimeters exhibit good linearity and agreement during FLASH X-ray irradiation. The monitors show good linearity to dose rate, with short-term fluctuations within 1.5 % for the diamond monitor. The discrepancy between measured absorbed dose and dose protocol is typically less than 4 %. The X-ray energy spectra on PARTER are comparable to those for megavoltage CONV linacs operating in flattening filter-free mode. The maximum field size of the FLASH beam is 4.5 cm × 4.5 cm. The FLASH dose profile demonstrates satisfactory flatness (1.04) and similar penumbra compared to clinical CONV linac, while the percentage depth dose curve of FLASH X-rays is steeper than that of the clinical megavoltage CONV X-ray. ConclusionsPARTER represents a pioneering platform for conducting megavolts FLASH X-ray irradiation in biological experiments. It effectively fulfills the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades to meet increasingly demanding performance criteria.

Surface Dose and Skin Toxicity Analysis in Breast Cancer Radiotherapy after Conserving Surgery with Five Treatment Modalities

The present study aimed to evaluate surface dose and skin toxicity in breast cancer after breast-conserving surgery with five treatment modalities: flattening filter mode of intensity modulated radiation therapy (IMRT-FF,6MV), flattening filter-free mode of intensity modulated radiation therapy (IMRT-FFF,6MV), direct mode of TOMO (TOMO-direct, FFF, 6MV), helical mode of TOMO (TOMO-helical, FFF, 6MV), intensity modulated proton therapy (IMPT, spot scanning). Ten patients with breast cancer treated at our institution after breast-conserving surgery were randomly selected for this study. Five plans were designed for each patient with the same target coverage and the prescription of 50Gy/25f, IMRT-6FF, IMRT-6FFF, TOMO-direct, TOMO-helical, and IMPT. Based on CT datasets, IMRT-6FFF, TOMO-direct, TOMO-helical, and IMPT were compared to IMRT-6FF with skin dose and skin toxicity. Among the five plannings, the angles of the IMRT-6FF vs. IMRT-6FFF and TOMO-direct were the same. We extracted the relative complement in the Body of its 3Derosion defined by a spherical structuring element of radius r = 3 mm and r = 5mm (skin3 and skin5). To calculate the relative Dose-surface histograms (DSH), we used the surface of patients receiving at least 5Gy to delimit the breast region's skin area and normalize the absolute DSH. Skin dose were assessed with V5Gy, V10Gy, V15Gy, V20Gy, V25Gy, V30Gy, V40Gy, V45Gy, V50Gy of the structure of skin3 and skin5. The published NTCP LKB (normal tissue complication probability, Lyman-Kutcher-Burman) model (TD50 = 39 Gy,m = 0.14,n = 0.38) was employed to evaluate severe acute radiation-induced skin toxicity. There was no statistically significant difference between the structure of skin3 and skin5 between IMRT-6FF and IMRT-6FFF. For the same PTV coverage, the TOMO-helical plans had significantly higher surface dose in terms of V5Gy, V10Gy, and V15Gy than the IMRT plans (p <0.005). For structure of skin3, mean V30Gy, V35Gy, V40Gy, V45Gy, V50Gy were (64.0%,65.8%,79.0%,70.0%,64.6%), (51.3%,55.4%,74.3%,61.7%,59.5%), (32.4%,36.6%,65.2%,53.0%,53.0%), (13.7%,14.1%,45.8%,35.7%,37.6%), (1.6%/0.8%/12.2%,6.6%,1.0%). For the structure of skin5, mean V30Gy, V35Gy, V40Gy, V45Gy, V50Gy were (66.1%,67.1%,76.4%,68.6%,62.6%), (57.9%,60.4%,72.3%,61.2%,57.7%), (45.5%,48.4%,65.2%,53.9%,51.8%), (28.4%,30.8%,51.2%,42.0%,40.0%), (6.8%,6.3%,22.6%,17.9%,8.0%).Compared to IMRT-6FF, TOMO-direct and TOMO-helical had higher surface dose(p<0.05). For IMRT-6FF/IMRT-6FFF/TOMO-direct/TOMO-helical/IMPT, the mean ratio of severe acute radiational skin toxicity were14.7%,17.1%,46.3%,29.4%, and 24.1%. For TOMO-direct and TOMO-helical planning, the skin dose and toxicity ratio were higher than IMRT-6FF. Compared to IMRT-6FF, V45Gy of skin3 and V40Gy of skin5 of IMPT were higher than IMRT-6FF, while the skin toxicity ratio was no significant difference.

Changes in Target Coverage and Dose to the Normal Brain during Fractionated Stereotactic Radiotherapy for Metastatic Brain Tumors

Fractionated stereotactic radiotherapy (SRT) has been applied to large brain metastases to reduce the risk of radiation necrosis. For fractionated SRT, potential of interfractional tumor changes during the treatment period, such as tumor size, shape, and geometry, must be considered to improve the tumor local control. Our center performs adaptive re-planning for large brain metastases based on repeat MRI verification with a contrast agent in the middle of the treatment period. Purpose of this study is to evaluate the dosimetric impact of the changes in tumor size, shape, and geometry on the doses to the targets and normal brain in patients with brain metastases undergoing fractionated SRT. Fifteen solitary large intracranial metastatic lesions treated with fractionated SRT were investigated. Standardized planning MRI (MRI-1) and repeat verification MRI (MRI-2) were performed during the middle of the irradiation period. The GTV on the MRI-1 and MRI-2 scans was contoured by the same oncologist. The PTV was created by adding an isotropic margin of 1 mm from the GTV in all directions. Volumetric modulated arc therapy (VMAT) with beam energies of 6 MV (flattening filter-free mode) was used and plans were normalized such that PTV D95% or D98% was equal to the prescribed dose. Beam configuration and intensity on the initial VMAT plan were used to evaluate the dose to the tumor and the normal brain on MRI-2. We evaluated the impact of D98% on the GTV using the plans on the MRI-1 and MRI-2 scans. For the normal brain, the V90%, V80%, and V50% were investigated. The median GTV changed from 9.8 cc (range of 3.2-33.0 cc) to 9.7 cc (range of 2.8-36.5 cc) (p = 0.482). Three and four tumors exhibited volume shrinkage and enlargement changes of >10%. Five tumors exhibited volume shrinkage and enlargement changes of <10%. Three tumors showed no volume changes. Of the 15 large brain metastases, 12 tumors required treatment plan modification. The dosimetric parameters of the GTV, PTV, and normal brain did not significantly differ between the MRI-1 and MRI-2 scans. Regarding the tumor dose, the D98% to the GTV increased in patients with tumor shrinkage because of dose inhomogeneity and decreased in patients with tumor enlargement. The V90%, V80%, and V50% increase with decreasing tumor volumes and were linearly related to the tumor volume difference, with a coefficient of determination of 0.97, 0.98, and 0.97, respectively. Our study demonstrated the usefulness of repeat verification MRI for adaptive radiotherapy in the middle of the treatment period due to changes in tumor size, shape, and geometry in patients with brain metastases. Repeated MRI should be considered to evaluate the dose to the target and normal brain, which improves tumor local control and reduces brain necrosis, to reduce the magnitude of underdosing to the target or overdosing to the normal brain during the treatment period.

Volumetric modulated arc therapy for hippocampal-sparing prophylactic cranial irradiation: Planning comparison of Halcyon and C-arm accelerators.

The purpose of the study was to evaluate the dosimetry of the Halcyon in prophylactic cranial irradiation (PCI) with volumetric modulated arc therapy (VMAT) and hippocampal-sparing for small cell lung cancer (SCLC). Five VMAT plans were designed on CT images of 15 patients diagnosed with SCLC and received PCI. Three plans with two full arcs were generated on the Trilogy and the TrueBeam accelerators, and flattening filter (FF) and flattening filter free (FFF) modes were used on TrueBeam. Two Halcyon plans with two and three full arcs were generated, referred to as H-2A and H-3A, respectively. The prescription dose was 25 Gy in 2.5-Gy fractions. The dose limit for hippocampus were D100 ≤ 9Gy and Dmax ≤ 16Gy. The Wilcoxon matched-paired signed-rank test was used to evaluate the significance of the observed differences between the five plans. H-2A plans significantly increased the D2 of PTV, and H-3A plans showed comparable or even better target dosimetry (better conformity) compared to the three plans on C-arm accelerators. Compared to T and TB plans, the two Halcyon plans significantly reduced the D100 and mean doses of bilateral hippocampus, the mean doses of eyeballs, and the maximum doses of lenses. D100 of hippocampus was reduced in TrueBeam plans comparing to Trilogy plans. The FFF plans on TrueBeam also represented advantages in Dmean and D100 of hippocampas, Dmean and Dmax of eyeballs, and the Dmax of lenses compared to FF plans. Halcyon plans and TrueBeam plans with FFF mode increased the MUs compared to FF plans. Comparing to H-2A, the H-3A plans exhibited additional dosimetric advantages, including D2, CI and HI of PTV, as well as the maximum and mean doses of hippocampus and eyeballs, and the maximum doses of optic nerves and brainstem. The two Halcyon plans significantly reduced the delivery time and showed the higher gamma passing rate than the three plans of C-arm accelerators. Compared with the C-arm accelerators, the dose of hippocampus and the delivery times on Halcyon are relatively significantly reduced for hippocampal-sparing PCI. Three arcs are recommended for VMAT plans with the Halcyon in hippocampal-sparing PCI.

Delivery of a VMAT technique with flattening filter (FF) and flattening filter free (FFF) mode for whole breast irradiation with five fractions (FAST-Forward trial).

To investigate the feasibility of volumetric modulated arc therapy (VMAT) delivery for whole breast irradiation with a 5-fraction regimen according to the FAST-Forward trial. Recently, we treated 10 patients with carcinoma of the left breast after breast conserving surgery. The dose prescription to the PTV was 26 Gy in 5 fractions. Treatment plans were produced using a VMAT technique with the Eclipse treatment planning system for 6 MV flattening filter (FF) and FF free (FFF) beams. Dose volume histograms (DVHs) for the PTV and the organs at risk (OARs), the ipsilateral lung and heart, were compared with the dose constraints specified in the FAST-Forward trial (PTV, D95 > 95%, D5 < 105%, D2 < 107% and Dmax < 110%; ipsilateral lung, D15 < 8Gy; Heart, D30 < 1.5Gy and D5 < 7Gy). Furthermore, conformity index (CI), homogeneity index (HI) and dose to the heart, contralateral lung, contralateral breast, and left anterior descending artery (LAD), were also assessed. Mean ± SD D95(%), D5(%), D2(%), and Dmax (%) for PTV were 97.75 ± 1.12, 105.2 ± 0.82, 105.90 ± 0.89, 109.36 ± 1.00 (FF) and 96.46 ± 0.75, 103.97 ± 0.97, 104.70 ± 1.09, 108.58 ± 1.33 (FFF) respectively. The mean ± SD CI was 1.07 ± 0.05 (FF), 1.048 ± 0.06 (FFF) and HI was 0.11 ± 0.02 (FF), 0.10 ± 0.02 (FFF). Dose constraints for OARs were met for both treatment techniques. However, D15 (Gy) for ipsilateral lung was 3.0% lower with FFF beams. In contrast, D5 (Gy) for heart was 9.0% higher with FFF beams. The dose difference between FF and FFF beams for other OARs such as contralateral lung-D10 (Gy) contralateral breast-D5 (Gy) and LAD was up to 6.0%. Both FF and FFF methods met the acceptable criteria. However, the treatment plans with FFF mode were more conformal and provided greater target homogeneity.

SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study.

In recent years, stereotactic body radiation therapy (SBRT) has gained popularity among clinical methods for the treatment of medium and low risk prostate cancer (PCa), mainly as an alternative to surgery. The hypo-fractionated regimen allows the administration of high doses of radiation in a small number of fractions; such a fractionation is possible by exploiting the different intrinsic prostate radiosensitivity compared with the surrounding healthy tissues. In addition, SBRT treatment guaranteed a better quality of life compared with surgery, avoiding risks, aftermaths, and possible complications. At present, most stereotactic prostate treatments are performed with the CyberKnife (CK) system, which is an accelerator exclusively dedicated for stereotaxis and it is not widely spread in every radiotherapy centre like a classic linear accelerator (LINAC). To be fair, a stereotactic treatment is achievable also by using a LINAC through Volumetric Modulated Arc Therapy (VMAT), but some precautions must be taken. The aim of this work is to carry out a dosimetric comparison between these two methodologies. In order to pursue such a goal, two groups of patients were selected at Instituto Nazionale Tumori—IRCCS Fondazione G. Pascale: the first group consisting of ten patients previously treated with a SBRT performed with CK; the second one was composed of ten patients who received a hypo-fractionated VMAT treatment and replanned in VMAT-SBRT flattening filter free mode (FFF). The two SBRT techniques were rescaled at the same target coverage and compared by normal tissue sparing, dose distribution parameters and delivery time. All organs at risk (OAR) constraints were achieved by both platforms. CK exhibits higher performances in terms of dose delivery; nevertheless, the general satisfying dosimetric results and the significantly shorter delivery time make VMAT-FFF an attractive and reasonable alternative SBRT technique for the treatment of localized prostate cancer.

Real-time two dimensional dosimetry using Al2O3:C and Al2O3:C,Mg films

The Investigations of this article focus on the response of Al2O3:C and Al2O3:C,Mg radioluminescence films for medical dosimetry in various MV photon beams. A dosimetry system was configured using a scientific camera, attached to the head of the linear accelerator (LINAC), facing the beam’s isocenter, where the films were placed. By using the appropriate filter and lens it is possible to measure real time two-dimensional dose-rate distributions. The key findings are that Al2O3:C,Mg films present a clear advantage compared to Al2O3:C ones, with no interference from afterglow, better film uniformity, high spatial resolution and suitability for small field beam dosimetry, while giving overall good dose-rate response in Flattening Filter (FF) and Flattening Filter Free (FFF) modes. The results show that our system can be used for planar real time dose rate assessment in medical photon dosimetry with manageable correction factors.

Per-fraction positional and dosimetric performance of prone breast tangential radiotherapy on Halcyon\u2122 linear accelerator assessed with daily rapid kilo-voltage cone beam computed tomography: a single-institution pilot study

BackgroundThis study investigates daily breast geometry and delivered dose to prone-positioned patients undergoing tangential whole breast radiation therapy (WBRT) on an O-ring linear accelerator with 6X flattening filter free mode (6X-FFF), planned with electronic compensation (ECOMP) method. Most practices rely on skin marks or daily planar image matching for prone breast WBRT. This system provides low dose daily CBCT, which was used to study daily robustness of delivered dose parameters for prone-positioned WBRT.MethodsEight patients treated with 16-fraction prone-breast WBRT were retrospectively studied. Planning CTs were deformed to daily CBCT to generate daily synthetic CTs, on which delivered dose distributions were calculated. A total of 8 × 16 = 128 synthetic CTs were generated. Consensus ASTRO definition was used to contour Breast PTV Eval for each daily deformed CT. Breast PTV Eval coverage (V90%) and hotspot (V105% and Dmax) were monitored daily to compare prescription dose with daily delivered dose. Various predictors including patient weight, breast width diameter (BWD), and Dice similarity coefficient (DSC) were fit into an analysis of covariance model predicting V90% and V105% deviation from prescribed (ΔV90%, ΔV105%). Statistical significance is indicated with asterisks (* for p < 0.05; ** for p < 0.001).ResultsDaily delivered Breast PTV Eval V90% was moderately smaller than prescribed (median ΔV90% = − 0.1%*), while V105% was much larger (median ΔV105% = + 10.1%** or + 92.4 cc**). Patient’s weight loss correlated with significantly increased ΔV105% (+ 4.6%/ − 1% weight, R2 = 0.4**) and moderately decreased ΔV90% (− 0.071%/ − 1% wt., R2 = 0.2**). Comprehensive ANCOVA models indicated three factors affect ΔV90% and ΔV105% the most: (1) BWD decrease (− 0.09%* and + 10%**/ − 1 cm respectively), (2) PTV Eval volume decrease (− 0.4%** and + 9%**/ − 100 cc), and for ΔV105% only, (3) the extent of breast deformation (+ 10%**/ − 0.01 DSC). Breast PTV Eval volume also decreased with time (− 2.21*cc/fx), possibly indicating seroma resolution and increase in V105% over time.ConclusionsDaily CBCT revealed key delivered dose parameters vary significantly for patients undergoing tangential prone breast WBRT planned with ECOMP using 6X-FFF. Patient weight, BWD, and breast shape deformation could be used to predict dosimetric variations from prescribed. Preliminary findings suggest an adaptive plan based on daily CBCT could reduce excessive dose to the breast.

Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter.

Men treated for localized prostate cancer by radiotherapy have often a remaining life span of 10 yr or more. Therefore, the risk for secondary malignancies should be taken into account. Plans for ten patients were evaluated which had been performed on an Oncentra® treatment planning system for a treatment with an Elekta Synergy™ linac with Agility™ head. The investigated techniques involved IMRT and VMTA with and without flattening filter. Different dose response models were applied for secondary carcinoma and sarcoma risk in the treated region and also in the periphery. As organs at risk we regarded for carcinoma risk urinary bladder, rectum, colon, esophagus, thyroid, and for sarcoma risk bone and soft tissue. The excess absolute risk (EAR) was found very similar in the treated region for both techniques (IMRT and VMAT) and also for both with and without flattening filter. The secondary sarcoma risk resulted about one magnitude smaller than the secondary carcinoma risk. The EAR to the peripheral organs was statistically significant reduced by application of the flattening filter free mode concerning the flattening filter as main source of scattered dose. Application of flattening filter free mode can thus support to reduce second malignancy risk for patients with localized prostate cancer.

The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma

BackgroundThis planning study compares different radiotherapy techniques for patients with pituitary adenoma, including flatness filter free mode (FFF), concerning plan quality and secondary malignancies for potentially young patients. The flatness filter has been described as main source of photon scatter.Material and methodsEleven patients with pituitary adenoma were included. An Elekta Synergy™ linac was used in the treatment planning system Oncentra® and for the measurements. 3D plans, IMRT, and VMAT plans and non-coplanar varieties were considered. The plan quality was evaluated regarding homogeneity, conformity, delivery time and dose to the organs at risk. The secondary malignancy risk was calculated from dose volume data and from measured dose to the periphery using different models for carcinoma and sarcoma risk.ResultsThe homogeneity and conformity were nearly unchanged with and without flattening filter, neither was the delivery time found substantively different. VMAT plans were more homogenous, conformal and faster in delivery than IMRT plans. The secondary cancer risk was reduced with FFF both in the treated region and in the periphery. VMAT plans resulted in a higher secondary brain cancer risk than IMRT plans, but the risk for secondary peripheral cancer was reduced. Secondary sarcoma risk plays a minor role. No advantage was found for non-coplanar techniques. The FFF delivery times were not shortened due to additional monitor units needed and technical limitations. The risk for secondary brain cancer seems to depend on the irradiated volume. Secondary sarcoma risk is much smaller than carcinoma risk in accordance to the results of the atomic bomb survivors. The reduction of the peripheral dose and resulting secondary malignancy risk for FFF is statistically significant. However, it is negligible in comparison to the risk in the treated region.ConclusionTreatments with FFF can reduce secondary malignancy risk while retaining similar quality as with flattening filter and should be preferred. VMAT plans show the best plan quality combined with lowest peripheral secondary malignancy risk, but highest level of second brain cancer risk. Taking this into account VMAT FFF seems the most advantageous technique for the treatment of pituitary adenomas with the given equipment.

81 Application of the TRS-483 correction factors on output ratios measurements for 8 detectors in stereotactic radiosurgery with cones

Introduction. The purpose of this work is to assess correction factors performances from TRS-483 [ [1] International Atomic Energy Agency. Dosimetrie of small static fields used in external beam radiotherapy. Rapport n483, 211 pages, Vienne; 2017. Google Scholar ] for output ratio (OR) determination in clinical 6 MV with flattening filter (WFF) Clinac and 6 MV flattening filter free (FFF) Truebeam stereotactic radiosurgery mode for cone irradiation using EBT3 films as reference [ [2] Girardi A. et al. Small field correction factors determination for the IBA razor nano chamber and the IBA razor chamber. Phys Med. 2018; 52: 151-152 Abstract Full Text PDF Google Scholar ].

Reconstruction of the electron source intensity distribution of a clinical linear accelerator using in-air measurements and a genetic algorithm.

Background and purposeThe electron source intensity distribution of a clinical linear accelerator has a great influence on the calculation of output factors for small radiation fields where source occlusion by the collimating devices takes place. The purpose of this study was to present a new method for the electron source reconstruction problem.Materials and methodsThe measurements were performed in-air using diode and 6 MV 1 × 1 cm2 photon field in flattening filter-free mode. In Monte Carlo simulation, an electron target area was divided into a number of square subsources. Then, the in-air doses in 2D silicon chip array were calculated individually from each subsource. A genetic algorithm search was applied in order to determine the optimal weight factors for all subsources that provide the best agreement between simulated and measured doses.ResultsIt was found that the reconstructed electron source intensity from a clinical linear accelerator has the two-dimensional elliptical double Gaussian distribution. The source intensity distribution consisted of two intensity components along the in-plane (x) and cross-plane (y) directions characterized by full width half-maximum (FWHM): FWHMx1 = 0.27 cm, FWHMx2 = 0.08 cm, FWHMy1 = 0.24 cm, FWHMy2 = 0.06 cm, where broader components are 81% and 53% of the total intensity along × and y axis respectively.ConclusionsThe obtained results demonstrated an elliptical double Gaussian intensity distribution of the incident electron source. We anticipate that the proposed method has universal applications independent of the type of linear accelerator, modality or energy.

The comparison of spatial resolution of ion chamber, diode, and EBT3 film based on the dose profile

Background: It is essential for the physicist to quantify the dose of the radiation prior and during cancer treatment to ensure proper execution of the treatment plan. The most common way to measure the dose is utilizing Farmer chamber. The limitation of Farmer chamber is that it only provides dose of a specific point, while the beam dose profile is needed for the planning system. The Gafchromic EBT3 film can provide a quantitative dose profile in a 2D space. The EBT3 film has low energy dependence, similar effective atomic number to water, and self-developing; making it an ideal candidate for dose profile measurement. Methods: Dose profiles of EBT3 was measured, analyzed and compared to semiflex chamber and EDGE detector under same conditions. The EBT3 films were placed at the center of RW3 water phantom (30×30×30 cm 3 ) under flattening filter free (FFF) Mode of Linac. The EBT3 films were calibrated by additional RW3 with a Farmer chamber under the stacked RW3 water phantom. Percentage depth dose (PDD) and Matlab were used to fit the dose curve of EBT3 and the results are presented. Results: The penumbra of the measured dose profile through EBT3 film demonstrated little differences when comparing with that of the EDGE detector and noticeable differences when compared to that of the semiflex chamber. For a field size of 2×2 cm 2 , (b=0.08, depth of 5 cm, beam off central axis 0.8 cm), the measured difference of dose profile between EBT3 and EDGE detector is –2.24%. Under the same conditions, the dose profile difference between EBT3 and semiflex chamber is 10.59%. Conclusions: This study shows that EDGE detector has the highest spatial resolution to the dose profile. EBT3 film in combination with solid phantom can quickly sample dose profile in 2D. EBT3 film can be considered to be an excellent quality assurance (QA) tool with accurate dosimetry, a good spatial resolution and tolerable dose uncertainty.

Radiation Oncology-External-Beam Radiation Therapy.

The application of structural shielding design techniques and goals as outlined in the National Council on Radiation Protection and Measurements Report 151, Structural Shielding Design and Evaluation for Megavoltage X- and Gamma-Ray Radiotherapy Facilities (2005), continues to be the basis for treatment vault design in 2018 with some updated information. Treatment techniques have changed significantly with the dominant usage of intensity-modulated radiation therapy techniques today based on concurrent imaging. Some of the developments in linear accelerator technology over the past 15 y include flattening filter-free modes, which enable higher instantaneous dose rates; three-dimensional conformal radiation therapy resulting in potentially higher workloads since healthy tissue is spared; improved intensity-modulated radiation therapy treatment delivery systems with lower monitor units per centigray delivered than traditional step and shoot intensity-modulated radiation therapy; stereotactic body radiation therapy with higher treatment fractions and increased workloads; and increased use of stereotactic radiosurgery with conventional linear accelerators as well as robotic arm-mounted linear accelerators with higher treatment fractions. These new treatment units also incorporate multiple-energy x-ray beams (2 to 5 MV typical), which require a significant change in the specification of a workload to be used in each vault. As the equipment in radiation oncology departments has evolved to state-of-the-art modalities, the requirements for adequate radiation shielding for these modalities has become more rigorous. Architectural designs no longer depend on standard maze design rectangular rooms. Innovative layouts and utilization of multiple layers of shielding materials allow much greater flexibility in room designs. Maze-less rooms with direct-shielded doors are part of these challenging designs and are very common today. Use of multiple-density concrete blocks allows quicker construction of vaults and requires less space for the equivalent shielding provided. Combinations of high-density or normal-density concrete, steel, and lead are used in designs to make optimum use of available space and cost. Additional shielding needed at the edges of these single- or bi-parting sliding doors as well as baffle designs for heating, ventilation, and air conditioning systems and communication cable penetrations require detailed calculations. Examples of these designs will be given in this presentation. Consideration of the radiation levels around the planned vault must also include adjacent multistory buildings.

Automated noncoplanar treatment planning strategy in stereotactic radiosurgery of multiple cranial metastases: HyperArc and CyberKnife dose distributions

The purpose of this study was to evaluate and compare the dosimetric effects of HyperArc-based stereotactic radiosurgery (SRS) and a robotic radiosurgery system-based planning using CyberKnife for multiple cranial metastases. In total, 11 cancer patients with multiple cranial metastases (3 to 5 tumors) treated with CyberKnife were examined. These patients were replanned using HyperArc (Varian Medical Systems, Palo Alto, USA). HyperArc plan were designed using 4 noncoplanar arc single-isocenter VMAT in 6 MV flattening filter free mode for simulated delivery with the True beam STx (Varian). The prescription dose was 23 Gy at single fraction. Dosimetric differences and blinded clinician scoring differences were evaluated. Conformity index (CI) and gradient index (GI) were 0.60 ± 0.11 and 3.94 ± 0.74, respectively, for the CyberKnife plan and 0.87 ± 0.08 and 5.31 ± 1.42, respectively, for the HyperArc plan (p < 0.05). Total brain V12-gross tumor volumes (GTVs) for the CyberKnife and HyperArc plans were 5.26 ± 2.83 and 4.02 ± 1.71 cm3, respectively. These results indicate that HyperArc plan showed better CI and total brain V12-GTV, while CyberKnife plan showed better GI. A blinded physician scoring evaluation did not show significant differences between CyberKnife and HyperArc plans. The HyperArc-based SRS plan is comparable with the CyberKnife plan, suggesting a greater potential to emerge as a suitable tool for SRS of multiple brain metastases.

Is attenuation technique sensitive enough to be used to make distinction between FF and FFF spectrum of therapy linac

The purpose of this study was to check if attenuation analysis is sensitive enough to make a distinction between photon energy spectra of standard accelerators and accelerators operating without a field flattening filter. Attenuation measurements were performed in two operating modes of a medical linear accelerator: with a flattening filter and without it, at nominal energy of 6 MV. Numerical and Laplace transform pair methods were used for spectra reconstruction. Although the difference between two attenuation curves is very small, as expected both reconstruction techniques produce slightly softer spectra at flattening filter free mode. The most important conclusion of this pilot study is that attenuation analysis can be a sensitive tool which is able to detect spectral differences between photon beams of an accelerator operating in two regimes.